Table 4.
Subgroup analyses for comparing nonosteoporosis to osteoporosis with or without MS.
| Group | No. of datasets | OR (95% CI) | P | P for heterogeneity | I 2 (%) |
|---|---|---|---|---|---|
| Definitions of MS | |||||
| NCEPATP III | 7 | 0.67 (0.54, 0.84) | <0.001 | 0.253 | 23.1 |
| CDS | 1 | 3.16 (1.28, 5.21) | 0.001 | — | — |
| Harmonization criteria | 2 | 0.54 (0.23, 1.30) | 0.169 | <0.001 | 82.1 |
| Country | |||||
| Asian | 7 | 0.86 (0.60, 1.23) | 0.404 | 0.003 | 69.6 |
| Non-Asian | 3 | 0.46 (0.23, 0.89) | 0.021 | 0.025 | 73.0 |
| Quality of studies | |||||
| Moderate | 3 | 0.80 (0.55, 1.15) | 0.231 | 0.400 | 0 |
| High | 7 | 0.70 (0.45, 1.08) | 0.108 | <0.001 | 80.6 |
| Confounding factors | |||||
| Adjusted | 7 | 0.81 (0.54, 1.21) | 0.303 | <0.001 | 75.5 |
| Unadjusted | 3 | 0.54 (0.31, 0.95) | 0.033 | <0.061 | 64.2 |
Note. MS, metabolic syndrome; OR, odds ratio; CI, confidence interval; NCEPATP III, the National Cholesterol Education Program Adult Treatment Panel III criteria; CDS, Chinese Diabetes Society.